Catalyst
Slingshot members are tracking this event:
Phase 2 pivotal first data of Brigatinib - ALTA trial for Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) due at ASCO 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARIA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Occurred Source:
http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=2175232
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Anaplastic Lymphoma Kinase Inhibitor, Alta Trial, Phase 2, Brigatinib, Nsclc, Alk In Lung Cancer Trial Of Ap26113
